CardiNor AS is a Norwegian biotech company established in June 2015 to handle the commercialization of secretoneurin (SN), an important new biomarker for cardiovascular disease (CVD).
The use of SN CVD is based on research carried out by world leading cardiac authorities at Akershus University Hospital, Oslo University Hospital and Akademiska Sjukhuset in Uppsala, Sweden.
SN is the only biomarker shown to be associated with biological processes linked to cardiomyocyte Ca2+ handling. This unique biological function explains why SN presents as an independent and strong predictor of mortality in all major patient cohorts, including ventricular arrhythmia, acute heart failure, acute respiratory failure patients with CVD and severe sepsis,
We are currently developing an easy to use ELISA (enzyme-linked immunosorbent assay) blood test to address the vast and untapped market potential in CVD patient diagnosis, risk stratification and monitoring. This will also involve clinical documentation, regulatory filing and market awareness programs.